TD Cowen raised the firm’s price target on Seagen (SGEN) to $229 from $145 and keeps a Market Perform rating on the shares. The analyst raised his price target following the announcement of the Pfizer (PFE) acquisition. While we do anticipate regulatory scrutiny, we do expect the deal to close in late 2023/early 2024. We also don’t anticipate any competing bids.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGEN:
- Seagen price target raised to $229 from $152 at Truist
- Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
- JPMorgan biotech/pharma analysts to hold analyst/industry conference call
- Seagen price target raised to $229 from $155 at RBC Capital
- Seagen price target raised to $229 from $141 at SVB Securities